drugset / Trial / NCT05876039

Optimal Dosage of Remifentanil for Vertebroplasty

NCT05876039

Phase 4 Completed 80 enrolled Tri-Service General Hospital (TSGH)
RandomizedParallel-groupDouble-blindTreatment

Summary

Percutaneous vertebroplasty has become a mainstay in the management of osteoporotic and malignant vertebral fractures. Procedural analgesia and sedation (PAS) with propofol and remifentanil may provides optimal hypnotic and analgesic effects.

Timeline

Start
2023-05-20
Primary completion
2024-08-24
Completion
2024-12-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Remifentanil Small molecule 1 ng/ml
Subject Remifentanil Small molecule 2 ng/ml

Indications

No indication recorded.